Últimas noticias sobre Calumet (NASDAQ:CLMT) Bolsa

Calumet

Calumet Specialty Prods

Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.

Calumet Inc

WIIM

CLMT

DINO

HAFN

LBRT

LTBR

SHEL

Shares of energy stocks are trading higher following President Trump's decision to implement a 90-day pause on reciprocal tariffs for all countries except China.

Wells Fargo analyst Roger Read maintains Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) with a Overweight and lowers the price target from $28 to $23.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Calumet, Lowers Price Target to $23

ACDC

CSAN

FANG

KLXE

Shares of energy companies are trading lower possibly amid ongoing weakness after crude levels dropped to 2021 levels following OPEC+'s decision to accelerate production hikes. Also, the industry may be declining due to global tensions related to US-China retaliatory tariffs.

Jim Carter and Dan Sheets have informed the Board of their decision not to seek re-election and to retire at the end of their terms following the Annual Meeting.
&nbsp;

Management

Calumet Reveals Intention To Nominate Julio Quintana And Karen Narwold To Board; Wasserstein Debt Opportunities Expresses Support

Calumet shares are trading higher following a UBS ratings upgrade from Sell to Neutral and amid overall strength in the oil and gas sector.

GEVO

GPRE

MPLX

NCSM

NEHC

OPAL

TRGP

Shares of oil and gas companies are trading higher amid weakness in the dollar after the US launched strikes on Houthi targets. Additionally, strong Chinese economic data could be lifting the demand outlook.

UBS analyst Manav Gupta upgrades Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) from Sell to Neutral and lowers the price target from $15 to $12.

Upgrades

UBS Upgrades Calumet to Neutral, Lowers Price Target to $12

Wells Fargo analyst Roger Read maintains Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) with a Overweight and lowers the price target from $29 to $28.

Wells Fargo Maintains Overweight on Calumet, Lowers Price Target to $28

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) with a Buy and maintains $33 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Calumet, Maintains $33 Price Target

Calumet Specialty Prods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.73) by 35.62 percent. This is a 20.34 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $949.50 million which beat the analyst consensus estimate of $921.76 million by 3.01 percent. This is a 2.76 percent decrease over sales of $976.50 million the same period last year.

Earnings

Earnings Beats

Calumet Specialty Prods Q4 2024 GAAP EPS $(0.47) Beats $(0.73) Estimate, Sales $949.50M Beat $921.76M Estimate

Calumet Streamlines Specialties Business With $110M Sale Of Royal Purple Industrial Line, Retains Texas Production Facility

<h3>Companies Reporting Before The Bell</h3>
• Frontline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $282.62 million. 
• Nordic American Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAT#NYSE">NAT</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $53.07 million. 
• Fluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNT#NASDAQ">FLNT</a>) is estimated to report quarterly loss at $0.23 per share on revenue of $68.06 million. 
• Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) is expected to report quarterly loss at $0.41 per share on revenue of $18.17 million. 
• Oxford Square Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXSQ#NASDAQ">OXSQ</a>) is projected to report quarterly earnings at $0.06 per share on revenue of $9.90 million. 
• Integral Ad Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $148.94 million. 
• PAR Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAR#NYSE">PAR</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $99.26 million. 
• ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) is expected to report quarterly earnings at $0.31 per share on revenue of $175.12 million. 
• TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $37.36 million. 
• Global Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLP#NYSE">GLP</a>) is estimated to report quarterly earnings at $0.90 per share on revenue of $5.80 billion. 
• Rapid Micro Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) is expected to report quarterly loss at $0.22 per share on revenue of $7.60 million. 
• FuboTV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $444.91 million. 
• Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) is expected to report quarterly loss at $0.08 per share on revenue of $21.01 million. 
• Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRP#NYSE">NRP</a>) is projected to report earnings for its fourth quarter. 
• Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) is expected to report quarterly loss at $0.37 per share on revenue of $191.93 million. 
• Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) is estimated to report quarterly loss at $0.36 per share on revenue of $929.11 million. 
• 1stdibs.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIBS#NASDAQ">DIBS</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $22.02 million. 
• LandBridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LB#NYSE">LB</a>) is projected to report quarterly earnings at $0.78 per share on revenue of $244.81 million. 
• Fulgent Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGT#NASDAQ">FLGT</a>) is estimated to report quarterly loss at $0.37 per share on revenue of $75.39 million. 
• Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) is estimated to report quarterly earnings at $0.53 per share on revenue of $2.73 billion. 
• Amneal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $700.83 million. 
• Banco Latinoamericano (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLX#NYSE">BLX</a>) is likely to report quarterly earnings at $0.44 per share on revenue of $251.03 million. 
• Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) is expected to report quarterly earnings at $3.23 per share on revenue of $1.18 billion. 
• Alpha Metallurgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMR#NYSE">AMR</a>) is estimated to report quarterly earnings at $1.12 per share on revenue of $683.10 million. 
• Docebo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $56.24 million. 
• Northwest Natural Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWN#NYSE">NWN</a>) is expected to report quarterly earnings at $1.49 per share on revenue of $395.05 million. 
<h3>Companies Reporting After The Bell</h3>
• BIT Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTCM#NYSE">BTCM</a>) is estimated to report earnings for its fourth quarter. 
• Monroe Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCC#NASDAQ">MRCC</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $14.99 million. 
• Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) is projected to report quarterly loss at $0.36 per share on revenue of $660 thousand. 
• Middlesex Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSEX#NASDAQ">MSEX</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $45.00 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMRX

ANIP

APLS

BFLY

BTCM

DCBO

DIBS

FLGT

FLNT

FUBO

GTLS

LGVN

MRCC

MSEX

OXSQ

RPID

RXRX

WULF

Earnings Scheduled For February 28, 2025

<ul>
<li>Initial loan proceeds of $782 million funded today</li>
<li>Balance of proceeds to be funded during planned expansion from 2025 through 2028</li>
<li>DOE loan guarantee facilitates expansion of Sustainable Aviation Fuel capacity to 300 million gallons per year</li>
</ul>

Montana Renewables Receives $782M Drawdown From $1.44B Guaranteed Loan Facility With DOE

Whales with a lot of money to spend have taken a noticeably bearish stance on Calumet.
Looking at options history for Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 60% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $212,963 and 6, calls, for a total amount of $272,600.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $13.0 and $17.0 for Calumet, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Calumet's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Calumet's whale trades within a strike price range from $13.0 to $17.0 in the last 30 days. 
<h3>Calumet Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739467839_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$1.15</td>
<td>$0.9</td>
<td>$1.0</td>
<td>$16.00</td>
<td>$121.4K</td>
<td>5.3K</td>
<td align="right">809</td>
</tr>
<tr>
<td>CLMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$3.6</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$13.00</td>
<td>$70.0K</td>
<td>994</td>
<td align="right">200</td>
</tr>
<tr>
<td>CLMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$2.95</td>
<td>$2.45</td>
<td>$2.85</td>
<td>$13.00</td>
<td>$57.0K</td>
<td>994</td>
<td align="right">400</td>
</tr>
<tr>
<td>CLMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.2</td>
<td>$1.0</td>
<td>$1.0</td>
<td>$16.00</td>
<td>$50.2K</td>
<td>1.6K</td>
<td align="right">501</td>
</tr>
<tr>
<td>CLMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.7</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$17.00</td>
<td>$36.1K</td>
<td>222</td>
<td align="right">24</td>
</tr>
</tbody>
</table>

<h3>About Calumet</h3>
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets.
In light of the recent options history for Calumet, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Calumet</h3>
<ul>
<li>With a trading volume of 1,031,424, the price of CLMT is down by -6.17%, reaching $16.34.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 12 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Calumet</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $24.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from UBS has revised its rating downward to Sell, adjusting the price target to $15. 
&#x2A; Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $33.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Calumet with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Decoding Calumet's Options Activity: What's the Big Picture?

U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday.
Shares of Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) rose sharply during Wednesday's session after the company reported better-than-expected fourth-quarter financial results and issued FY25 adjusted EPS <a href="https://in.benzinga.com/general/health-care/25/02/43643001/gilead-sciences-shares-push-higher-after-q4-report-heres-why">guidance above estimates</a>.
Gilead Sciences reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $1.70. Quarterly revenue came in at $7.56 billion which beat the analyst consensus estimate of $7.13 billion and is an increase over revenue of $7.11 billion from the same period last year.
Gilead Sciences shares jumped 8.1% to $103.88 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) shares jumped 30.7% to $88.07 after the company reported better-than-expected fourth-quarter financial results and issued FY25 revenue guidance above estimates. Multiple analysts upgraded the stock following the report.</li>
<li>AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) rose 19.6% to $14.82 after the company announced statistically significant week 12 data from the Phase 2b trial of rosnilimab in moderate-to-severe rheumatoid arthritis.</li>
<li>Mercury General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>) gained 17.4% to $58.80 after the company reported quarterly financial results. Raymond James upgraded the stock from Outperform to Strong Buy and raised its price target from $70 to $80.</li>
<li>EHang Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) rose 16.5% to $24.13.</li>
<li>Confluent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) gained 15.5% to $34.78 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Angi Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) surged 15% to $1.9850 following better-than-expected fourth-quarter sales and a year-over-year increase in EPS results.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) climbed 14.6% to $63.05 after the company reported quarterly earnings and revenue above estimates.</li>
<li>Calumet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) gained 13.3% to $18.00.</li>
<li>The Chefs&#8217; Warehouse, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>) gained 11.3% to $60.69 following better-than-expected quarterly reported financial results.</li>
<li>Sensata Technologies Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) surged 9.2% to $28.05 following a fourth-quarter adjusted EPS and revenue beat.</li>
<li>iQIYI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) gained 9.2% to $2.50.</li>
<li>VNET Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) rose 8.5% to $10.82.</li>
<li>CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) gained 8.4% to $42.95  after the company reported better-than-expected quarterly financial results and Barclays raised its price target on the stock from $55 to $56.</li>
<li>Prudential plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PUK#NYSE">PUK</a>) gained 6.1% to $18.10.</li>
<li>IAC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) surged 5.6% to $43.31 following strong quarterly sales.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43658834/this-ppg-industries-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-wednesday">This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday</a></li>
</ul>

Intraday Update

Movers

Trading Ideas

ANAB

ANGI

CFLT

CHEF

CRSP

GILD

UPST

VNET

Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler analyst David Amsellem downgraded Amphastar Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) from Overweight to Neutral and lowered the price target from $66 to $36. Amphastar Pharma shares closed at $33.39 on Monday. <a href="https://www.benzinga.com/quote/AMPH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Peter Arment downgraded Triumph Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGI#NYSE">TGI</a>) from Outperform to Neutral but raised the price target from $20 to $26. Triumph Group shares closed at $25.10 on Monday. <a href="https://www.benzinga.com/quote/TTGI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Randal Konik downgraded the rating for Ollie&#8217;s Bargain Outlet Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) from Buy to Hold and lowered the price target from $125 to $111. Ollie&#8217;s Bargain shares closed at $107.63 on Monday. <a href="https://www.benzinga.com/quote/OLLI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Manav Gupta downgraded Calumet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) from Neutral to Sell and cut the price target from $20.5 to $15. Calumet shares closed at $18.34 on Monday. <a href="https://www.benzinga.com/quote/CLMT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Trevor Allinson downgraded the rating for American Woodmark Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMWD#NASDAQ">AMWD</a>) from Outperform to Peer Perform. American Woodmark shares closed at $75.65 on Monday. <a href="https://www.benzinga.com/quote/AMWD/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying OLLI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="628" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23-1024x628.png" alt="" class="wp-image-764859" style="width:568px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23-1024x628.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23-768x471.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23.png 1077w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Downgrades

Pre-Market Outlook

AMPH

AMWD

OLLI

This Ollie's Bargain Outlet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Calumet shares are trading lower after UBS downgraded the stock from Neutral to Sell and cut its price target from $20.5 to $15.

UBS analyst Manav Gupta downgrades Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) from Neutral to Sell and lowers the price target from $20.5 to $15.

UBS Downgrades Calumet to Sell, Lowers Price Target to $15

Investors with a lot of money to spend have taken a bullish stance on Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with CLMT, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 20 options trades for Calumet.
This isn't normal.
The overall sentiment of these big-money traders is split between 85% bullish and 0%, bearish.
Out of all of the options we uncovered, 19 are puts, for a total amount of $833,524, and there was 1 call, for a total amount of $35,500.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $17.0 to $30.0 for Calumet over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Calumet's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Calumet's significant trades, within a strike price range of $17.0 to $30.0, over the past month.
<h3>Calumet Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736954132_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$12.6</td>
<td>$11.9</td>
<td>$11.64</td>
<td>$30.00</td>
<td>$216.2K</td>
<td>10</td>
<td>185</td>
</tr>
<tr>
<td>CLMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$12.5</td>
<td>$11.8</td>
<td>$11.95</td>
<td>$30.00</td>
<td>$92.2K</td>
<td>10</td>
<td>185</td>
</tr>
<tr>
<td>CLMT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$2.1</td>
<td>$1.9</td>
<td>$1.95</td>
<td>$17.00</td>
<td>$48.5K</td>
<td>1.0K</td>
<td>400</td>
</tr>
<tr>
<td>CLMT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$1.9</td>
<td>$1.85</td>
<td>$1.86</td>
<td>$17.00</td>
<td>$46.5K</td>
<td>1.0K</td>
<td>1.4K</td>
</tr>
<tr>
<td>CLMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$3.7</td>
<td>$3.4</td>
<td>$3.55</td>
<td>$25.00</td>
<td>$35.5K</td>
<td>365</td>
<td>100</td>
</tr>
</tbody>
</table>

<h3>About Calumet</h3>
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets.
<h3>Present Market Standing of Calumet</h3>
<ul>
<li>With a volume of 252,080, the price of CLMT is up 0.47% at $19.05. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 37 days.</li>
</ul>
<h3>What Analysts Are Saying About Calumet</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $33.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from HC Wainwright &amp; Co. has decided to maintain their Buy rating on Calumet, which currently sits at a price target of $33. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Calumet with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Check Out What Whales Are Doing With CLMT

Commodities

Press Releases

Calumet, Inc. to Release Fourth Quarter and Fiscal Year 2024 Earnings on February 28, 2025

Montana Renewables Receives First Drawdown from $1.44 Billion DOE Loan Facility

Calumet to Attend Raymond James Conference

Calumet Announces Sale of Assets Related to Industrial Portion of its Royal Purple® Business

Calumet Reports Fourth Quarter and Fiscal Year 2024 Results

Lubrication Engineers to Acquire Industrial Brands & Products of Royal Purple

Calumet to Attend Wolfe Research Conference

Calumet Announces Intention to Nominate Julio Quintana and Karen Narwold to Board of Directors; and Wasserstein Debt Opportunities Expresses Support

Calumet Announces Closing of Sale of Assets Related to Industrial Portion of its Royal Purple® Business

Comments

Calumet

Noticias

Últimas noticias sobre Calumet (NASDAQ:CLMT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL